Stryker’s Cyber Hit, Robotics Strength Dominate Earnings Call

Stryker Corp ((SYK)) has held its Q1 earnings call. Read on for the main highlights of the call.

Stryker’s latest earnings call balanced a clear near‑term setback with notable resilience and optimism. Management detailed how a late‑quarter cyber incident distorted first‑quarter results, compressing margins and EPS, yet emphasized rapid operational recovery, strong robotic demand, and enough underlying strength to reaffirm full‑year growth and earnings guidance.

Organic Growth Holds Up Amid Cyber Shock

Stryker posted 2.4% organic net sales growth in Q1, with 1.9% in the U.S. and 3.9% internationally. Executives stressed that demand across businesses remained healthy, arguing that the modest growth reflects timing and disruption from the cyber event rather than a deterioration in end‑market fundamentals.

Full‑Year Outlook Reaffirmed Despite Volatility

Management maintained its 2026 outlook for 8.0%–9.5% organic sales growth and adjusted EPS of $14.90–$15.10. The team expressed confidence that most lost Q1 revenue will be recaptured through the year, with some catch‑up in Q2 and more heavily weighted to the second half.

Fast Recovery From Cyber Incident

By the week of April 1, Stryker’s global manufacturing network was back to full operation after the cyber attack. Leaders highlighted successful removal of the intruder, restoration from backups, and a recovery process that prioritized patient care and customer support while systems were brought back online.

Robotics: Record Mako Quarter Fuels Growth Story

The company delivered its best‑ever first quarter for Mako robotic installations in both the U.S. and international markets, with utilization rates continuing to rise. Early feedback on the Mako Shoulder application has been positive, and a full launch on the Mako 4 platform is slated for mid‑year alongside momentum for the new RPS handheld.

Ortho Tech Reorganization Targets Simpler Customer Experience

Stryker unveiled a new Ortho Tech business that combines Mako, Enabling Technologies, and Orthopaedic Instruments into a single unit. Management says this integration should simplify the buying experience for surgeons and hospitals, accelerate innovation, and speed product introductions, with segment reporting updated to reflect the new structure.

M&A Engine Turns With AVS Deal and Pipeline

The company announced an agreement to acquire Amplitude Vascular Systems, expected to close in Q2, expanding its peripheral vascular and cardiovascular portfolio. With gross debt to EBITDA of about 2.1x at quarter end, executives signaled ample capacity for further deals and described the broader M&A pipeline as active.

International Product Approvals Support Above‑Market Growth

Pangea secured approval in Europe following an earlier green light in Japan, and LIFEPAK devices also received European approvals. Management believes these launches will help Stryker grow faster than local markets internationally as production ramps and distribution networks scale.

Tax, Cash Flow, and Balance Sheet Remain Solid

Stryker reported a Q1 adjusted effective tax rate of 14.5% and guided to 15%–16% for the full year. Year‑to‑date cash from operations reached $581 million, and the company still expects about 70%–80% free cash flow conversion while holding its outlook for roughly $420 million of adjusted other income and expense.

Smart Hospital Push Through SmartCare Platform

The company launched its Smart Hospital initiative by combining Vocera with care.ai into a SmartCare unit. This integrated platform is aimed at delivering more connected, data‑driven hospital workflows, and management cited encouraging early reactions from customers exploring broader digital solutions.

Cyber Disruption Skews Q1 Performance

The late‑quarter cyber incident disrupted operations globally, delaying shipments and revenue recognition while devices were wiped and rebuilt. The event also forced management to limit some normal reporting detail as teams focused on multi‑week recovery efforts, which they say contributed to the unusual shape of first‑quarter results.

EPS and Margins Hit by Shutdowns and Tariffs

Adjusted EPS came in at $2.60, down $0.24 or 8.5% year over year, as limited sales growth and lost manufacturing absorption weighed on profitability. Adjusted gross margin slipped 190 basis points to 63.6%, and operating margin fell 180 basis points to 21.1%, with tariffs adding further pressure.

Higher Interest Costs Lift Other Expense

Adjusted other income and expense rose to $97 million in Q1, up $24 million from last year. The increase was driven primarily by higher interest expense tied to debt issued in 2025, including financing for the Inari transaction, and by lower interest income as cash balances and yields eased.

Working Capital and Cash Flow Temporarily Strained

Cash from operations of $581 million reflected the hit to net earnings from the cyber event and short‑term changes in working capital, notably inventories and receivables timing. Management acknowledged some one‑time and recovery‑related investments but stressed these remain within the boundaries of its full‑year guidance.

Deferred Procedures and Partial Revenue Loss

Certain procedures, especially capital‑intensive MedSurg cases for make‑to‑order products, were deferred or rescheduled due to the disruption. While executives expect much of this activity to shift into the third and fourth quarters, they cautioned that a limited number of urgent cases were permanently lost.

Tariff and Geopolitical Headwinds Still Manageable

Tariffs remained a drag on margins in Q1, with no similar impact in the prior‑year period, though management anticipates some improvement as the year progresses. They also noted that tensions in Iran and the broader Middle East modestly weighed on international growth, but the overall effect was described as limited.

Guidance: Recovery and Growth Still the Central Story

Looking ahead, Stryker reiterated its forecast for 8.0%–9.5% organic net sales growth and adjusted EPS of $14.90–$15.10, with a 15%–16% effective tax rate and about $420 million of other income and expense. Management expects modestly positive pricing, potential FX and rate tailwinds, gradual tariff relief, and a revenue catch‑up that begins in Q2 and accelerates in the second half.

Stryker’s call painted a picture of a high‑quality growth story temporarily disrupted by a cyber shock rather than by weakening demand. With robotics momentum, strategic reorganization, active deal‑making and reaffirmed guidance, investors are being asked to look through near‑term margin pressure and focus on the recovery arc and long‑term growth drivers.